New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens.
The antiretroviral activity of two new lipophilic derivatives of azidothymidine (AZT), N4-hexadecyl-2'-deoxyribocytidylyl-(3',5')-3'-azido-2',3'-deoxythy midine (N4-hexadecyldC-AZT) and N4-palmitoyl-2'-deoxyribocytidylyl-(3',5')-3'-azido-2',3'-deoxythy midine (N4-palmitoyldC-AZT) was evaluated in comparison to AZT. In vitro the drugs were tested in human immunodeficiency virus 1 (HIV-1) infected CD4+ HeLa and H9 cells. The in vivo antiviral effect of these derivatives was analysed in Rauscher leukemia virus (RLV) infected mice. The derivatives were incorporated into small liposomes. In vitro both derivatives inhibited virus proliferation in both HIV-1 infected cell lines in a similar dose-responsive manner as AZT. In a plaque reduction assay, using HeLa cells, the IC50 values were 0.035 microM for AZT, 0.5 microM for N4-hexadecyldC-AZT and 4.5 microM for N4-palmitoyldC-AZT, whereas p24 antigen analysis on H9 cells gave IC50 values of 0.005 microM, 0.05 microM and 0.05 microM, respectively. RLV infected mice were treated with intermittent schedules i.p. or i.v. on days 1, 6, 11, and days 16 or 0, 3, 7, and 11 after infection. Regimens with further delayed drug application were on days 3, 7, and 11 and 7 and 11 only. While i.p. treatment with total doses of 380-1140 mg/kg free AZT resulted in 10-30% inhibition of RLV induced splenomegaly, the derivatives gave inhibitions of 37-94%. Late onset of treatment with the derivatives was significantly more effective as compared to free AZT. Intravenous treatment with N4-hexadecyldC-AZT was effective, but with AZT was inactive. The discrepancy in antiviral activity of the AZT derivatives found between the in vitro and in vivo test systems emphasizes the importance of investigating the activity of drug derivatives in vivo.
Schwendener
R A
RA
Department of Internal Medicine, University Hospital, Zürich, Switzerland.
Gowland
P
P
Horber
D H
DH
Zahner
R
R
Schertler
A
A
Schott
H
H
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000633:toxicity; D001772:Blood Cell Count / Q000187:drug effects; D003843:Deoxycytidine Monophosphate / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity; D054306:Dideoxynucleotides; D004355:Drug Stability; D005260:Female; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology*; D006367:HeLa Cells; D006801:Humans; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000821:virology; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D011925:Rauscher Virus; D012192:Retroviridae Infections / Q000188:drug therapy* / Q000821:virology; D014412:Tumor Virus Infections / Q000188:drug therapy* / Q000821:virology; D014779:Virus Replication / Q000187:drug effects*; D015215:Zidovudine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity
D000998:Antiviral Agents; D054306:Dideoxynucleotides; D008081:Liposomes; C089811:N(4)-hexadecyl-2'-deoxyribocytidylyl-(3',5')-3'-azido-2',3'-deoxythymidine; C089812:N(4)-palmitoyl-2'-deoxyribocytidylyl-(3',5')-3'-azido-2',3'-deoxythymidine; D003843:Deoxycytidine Monophosphate; D015215:Zidovudine